Myriad Genetics Inc. [MYGN] Stock trading around $15.63 per share: What’s Next?

Related

Share

Myriad Genetics Inc. [NASDAQ: MYGN] stock went on a downward path that fall over -3.46% on Wednesday, amounting to a one-week price increase of more than 0.84%. Over the last 12 months, MYGN stock dropped by -33.77%. The one-year Myriad Genetics Inc. stock forecast points to a potential upside of 16.28. The average equity rating for MYGN stock is currently 3.00, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $1.16 billion, with 74.50 million shares outstanding and 73.25 million shares in the current float. Compared to the average trading volume of 1.11M shares, MYGN stock reached a trading volume of 1002693 in the most recent trading day, which is why market watchdogs consider the stock to be active.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Guru’s Opinion on Myriad Genetics Inc. [MYGN]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MYGN shares is $18.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MYGN stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

BofA/Merrill have made an estimate for Myriad Genetics Inc. shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on September 26, 2019. While these analysts kept the previous recommendation, Piper Jaffray dropped their target price from $45 to $40. The new note on the price target was released on August 14, 2019, representing the official price target for Myriad Genetics Inc. stock. On August 01, 2019, analysts increased their price target for MYGN shares from 18 to 40.

The Average True Range (ATR) for Myriad Genetics Inc. is set at 0.90, with the Price to Sales ratio for MYGN stock in the period of the last 12 months amounting to 1.53. The Price to Book ratio for the last quarter was 1.20, with the Price to Cash per share for the same quarter was set at 2.44. Price to Free Cash Flow for MYGN in the course of the last twelve months was 21.97 with Quick ratio for the last quarter at 2.90.

MYGN Stock Performance Analysis:

Myriad Genetics Inc. [MYGN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.84. With this latest performance, MYGN shares dropped by -1.82% in over the last four-week period, additionally sinking by -37.53% over the last 6 months – not to mention a drop of -33.77% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MYGN stock in for the last two-week period is set at 53.53, with the RSI for the last a single of trading hit 53.61, and the three-weeks RSI is set at 52.06 for Myriad Genetics Inc. [MYGN]. The present Moving Average for the last 50 days of trading for this stock 14.85, while it was recorded at 16.14 for the last single week of trading, and 22.28 for the last 200 days.

Insight into Myriad Genetics Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Myriad Genetics Inc. [MYGN] shares currently have an operating margin of +4.54 and a Gross Margin at +69.42. Myriad Genetics Inc.’s Net Margin is presently recorded at +0.54.

Return on Total Capital for MYGN is now 3.36, given the latest momentum, and Return on Invested Capital for the company is 0.40. Return on Equity for this stock inclined to 0.45, with Return on Assets sitting at 0.32. When it comes to the capital structure of this company, Myriad Genetics Inc. [MYGN] has a Total Debt to Total Equity ratio set at 21.44. Additionally, MYGN Total Debt to Total Capital is recorded at 17.66, with Total Debt to Total Assets ending up at 14.02. Long-Term Debt to Equity for the company is recorded at 21.44, with the Long-Term Debt to Total Capital now at 17.66.

Reflecting on the efficiency of the workforce at the company, Myriad Genetics Inc. [MYGN] managed to generate an average of $1,769 per employee. Receivables Turnover for the company is 7.07 with a Total Asset Turnover recorded at a value of 0.59.Myriad Genetics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.90 and a Current Ratio set at 3.10.

MYGN Stock EPS

With the latest financial reports released by the company, Myriad Genetics Inc. posted 0.41/share EPS, while the average EPS was predicted by analysts to be reported at 0.47/share.When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -12.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MYGN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Myriad Genetics Inc. go to 8.10%.

Myriad Genetics Inc. [MYGN] Insider Position Details

There are presently around $1,209 million, in the hands of institutional investors. The top three institutional holders of MYGN stocks are: BLACKROCK INC. with ownership of 12,458,686, which is approximately -2.301% of the company’s market cap and around 1.10% of the total institutional ownership; BAILLIE GIFFORD & CO, holding 8,970,006 shares of the stock with an approximate value of $145.22 million in MYGN stocks shares; and VANGUARD GROUP INC, currently with $135.44 million in MYGN stock with ownership of nearly 0.539% of the company’s market capitalization.

Positions in Myriad Genetics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 98 institutional holders increased their position in Myriad Genetics Inc. [NASDAQ:MYGN] by around 6,574,699 shares. Additionally, 109 investors decreased positions by around 11,851,708 shares, while 38 investors held positions by with 56,271,863 shares. The mentioned changes placed institutional holdings at 74,698,270 shares, according to the latest SEC report filing. MYGN stock had 18 new institutional investments in for a total of 1,299,642 shares, while 50 institutional investors sold positions of 3,626,783 shares during the same period.

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam